Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Our AI scores Pure Bioscience, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Pure Bioscience, Inc. is a small-cap company with a market capitalization of $9M. It ranks number 9 by market capitalization among the 9 Miscellaneous Chemical Products issuers in our coverage with a current forecast. Its Gross Margin of 57.3% is the highest of the 9 peers that report one. Its Current Ratio of 0.27x is the lowest of the 8 peers that report one.
For PURE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -9.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 5.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, PURE included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Miscellaneous Chemical Products peers listed below that report each metric.
| Metric | PURE | Rank |
|---|---|---|
| Market Cap | $9M | 9/9 |
| EPS | $-0.02 | – |
| Revenue/Share | $0.02 | – |
| Metric | PURE | Rank |
|---|---|---|
| ROA | -208.1% | 7/7 |
| ROIC | 65.5% | 1/8 |
| Gross Margin | 57.3% | 1/9 |
| Operating Margin | -90.0% | 8/9 |
| Net Margin | -107.3% | 7/7 |
| EBT Margin | -90.0% | 8/9 |
| Tax Rate | 0.0% | – |
| Metric | PURE | Rank |
|---|---|---|
| Current Ratio | 0.27x | 8/8 |
| Quick Ratio | 0.23x | 8/8 |
| Interest Coverage | -4.8x | 6/8 |
| Working Capital | -$3M | 8/8 |
| Metric | PURE | Rank |
|---|---|---|
| Operating Cash Flow | -$2M | 7/9 |
| Metric | PURE | Rank |
|---|---|---|
| Asset Turnover | 1.94x | 1/7 |
| Receivables Turnover | 6.9x | – |
| Inventory Turnover | 5.1x | 5/8 |
| Fixed Assets Turnover | 289.4x | 1/6 |
| Days Sales Outstanding | 53 days | – |
| Days Inventory | 71 days | 4/8 |
| Payables Period | 302 days | 1/8 |
| Cash Conversion Cycle | -178 days | – |
| Metric | PURE | Rank |
|---|---|---|
| Total Revenue | $2M | 7/7 |
| Operating Income | -$2M | 7/9 |
| Net Income | -$2M | 5/7 |
| R&D Expense | $330K | 8/8 |
| SG&A Expense | $3M | 7/7 |
| Cost of Goods Sold | $990K | 9/9 |
| Metric | PURE | Rank |
|---|---|---|
| Shares Outstanding | 140M | – |
| Total Current Assets | $1M | |
| Cash & Short-term Investments | $570K | |
| Accounts Receivable | $330K | |
| Inventory | $190K | |
| Total Liabilities | $8M | |
| Short-term Debt | $4M |
Companies classified under the same SEC industry code as Pure Bioscience, Inc. (Miscellaneous Chemical Products): 9 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| PURE Pure Bioscience, Inc. | $9M | |
| ESI Element Solutions Inc | $7.61B | |
| CBT Cabot Corp | $3.67B | |
| WDFC Wd 40 Co | $2.97B | |
| FTK Flotek Industries Inc/Cn/ | $886M | |
| ASPI Asp Isotopes Inc. | $318M | |
| OEC Orion S.A. | $224M | |
| ARQ Arq, Inc. | $105M | |
| FSI Flexible Solutions International Inc | $78M |
Welcome to the PURE Bioscience Q3 2019 Results Conference Call. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an ...
EL CAJON, Calif., November 19, 2025--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE" or the "Company"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, ...
PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company," or "we"), creator of the patented non-toxic silver dihydrogen ...
Our AI scores Pure Bioscience, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For PURE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -9.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 5.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Pure Bioscience, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
9 issuers in our coverage, PURE included, share the SEC industry code Miscellaneous Chemical Products. The largest are: Element Solutions Inc (ESI), Cabot Corp (CBT), Wd 40 Co (WDFC), Flotek Industries Inc/Cn/ (FTK), Asp Isotopes Inc. (ASPI), Orion S.A. (OEC).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
